title: Kinase inhibitors for advanced medullary thyroid carcinoma.
abstract: The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.
authors.affiliation: Centre de Référence Tumeurs Réfractaires de la Thyroïde, Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris-Sud XI, Villejuif, France. schlumbg@igr.fr
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Massicotte
authors.forename: Camila L
authors.initials: CL
authors.lastname: Nascimento
authors.forename: Cécile
authors.initials: C
authors.lastname: Chougnet
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000473:pathology; D018278:Carcinoma, Neuroendocrine; D002986:Clinical Trials as Topic / Q000592:standards; D006801:Humans; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C452423:vandetanib